Cargando…
Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis
INTRODUCTION: A 28.2 μg twice-weekly formulation of teriparatide (2/W-TPD) was developed to provide comparably high efficacy for osteoporosis to a 56.5 μg once-weekly formulation while improving the safety and persistence rate. In the current study, we aimed to elucidate the real-world persistence o...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244578/ https://www.ncbi.nlm.nih.gov/pubmed/35759143 http://dx.doi.org/10.1007/s00774-022-01347-1 |
_version_ | 1784738553644711936 |
---|---|
author | Fujita, Ryo Endo, Tsutomu Takahata, Masahiko Haraya, Kentaro Suzuki, Hisataka Oda, Itaru Kanayama, Masahiro Asano, Tsuyoshi Shigenobu, Keiichi Iwata, Akira Yamada, Katsuhisa Takeuchi, Hirohito Ohura, Hisanori Yoneoka, Daisuke Iwasaki, Norimasa |
author_facet | Fujita, Ryo Endo, Tsutomu Takahata, Masahiko Haraya, Kentaro Suzuki, Hisataka Oda, Itaru Kanayama, Masahiro Asano, Tsuyoshi Shigenobu, Keiichi Iwata, Akira Yamada, Katsuhisa Takeuchi, Hirohito Ohura, Hisanori Yoneoka, Daisuke Iwasaki, Norimasa |
author_sort | Fujita, Ryo |
collection | PubMed |
description | INTRODUCTION: A 28.2 μg twice-weekly formulation of teriparatide (2/W-TPD) was developed to provide comparably high efficacy for osteoporosis to a 56.5 μg once-weekly formulation while improving the safety and persistence rate. In the current study, we aimed to elucidate the real-world persistence of 2/W-TPD and to identify the factors associated with the discontinuation of 2/W-TPD in patients with severe osteoporosis. MATERIALS AND METHODS: This retrospective study included 90 patients who were treated with 2/W-TPD at three hospitals in Japan. Patient information was collected, including age, sex, distance to the hospital, family structure, comorbidities, previous treatment for osteoporosis, timing of the injection, side effects and duration of 2/W-TPD treatment, barthel index (BI), and bone mineral density (BMD) of the lumbar spine and femoral neck. We examined the factors influencing 2/W-TPD discontinuation using the Cox proportional hazards model. RESULTS: The 12 month completion rate of 2/W-TPD therapy was 47.5%. The Cox hazard analysis identified side effects [Hazard Ratio (HR) = 14.59, P < 0.001], low BMD of the femoral neck (HR = 0.04, P = 0.002), and morning injection (HR = 3.29, P = 0.006) as risk factors influencing the discontinuation of 2/W-TPD. Other variables, including age, did not contribute to the continuation of 2/W-TPD. CONCLUSION: One year continuation rate of 2/W-TPD was higher than the previously reported value of the once-weekly formulation in real-world setting, probably due to the lower incidence of side effects. Introducing injection of 2/W-TPD may further improve the persistence of TPD therapy for osteoporosis. |
format | Online Article Text |
id | pubmed-9244578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-92445782022-06-30 Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis Fujita, Ryo Endo, Tsutomu Takahata, Masahiko Haraya, Kentaro Suzuki, Hisataka Oda, Itaru Kanayama, Masahiro Asano, Tsuyoshi Shigenobu, Keiichi Iwata, Akira Yamada, Katsuhisa Takeuchi, Hirohito Ohura, Hisanori Yoneoka, Daisuke Iwasaki, Norimasa J Bone Miner Metab Original Article INTRODUCTION: A 28.2 μg twice-weekly formulation of teriparatide (2/W-TPD) was developed to provide comparably high efficacy for osteoporosis to a 56.5 μg once-weekly formulation while improving the safety and persistence rate. In the current study, we aimed to elucidate the real-world persistence of 2/W-TPD and to identify the factors associated with the discontinuation of 2/W-TPD in patients with severe osteoporosis. MATERIALS AND METHODS: This retrospective study included 90 patients who were treated with 2/W-TPD at three hospitals in Japan. Patient information was collected, including age, sex, distance to the hospital, family structure, comorbidities, previous treatment for osteoporosis, timing of the injection, side effects and duration of 2/W-TPD treatment, barthel index (BI), and bone mineral density (BMD) of the lumbar spine and femoral neck. We examined the factors influencing 2/W-TPD discontinuation using the Cox proportional hazards model. RESULTS: The 12 month completion rate of 2/W-TPD therapy was 47.5%. The Cox hazard analysis identified side effects [Hazard Ratio (HR) = 14.59, P < 0.001], low BMD of the femoral neck (HR = 0.04, P = 0.002), and morning injection (HR = 3.29, P = 0.006) as risk factors influencing the discontinuation of 2/W-TPD. Other variables, including age, did not contribute to the continuation of 2/W-TPD. CONCLUSION: One year continuation rate of 2/W-TPD was higher than the previously reported value of the once-weekly formulation in real-world setting, probably due to the lower incidence of side effects. Introducing injection of 2/W-TPD may further improve the persistence of TPD therapy for osteoporosis. Springer Nature Singapore 2022-06-27 2022 /pmc/articles/PMC9244578/ /pubmed/35759143 http://dx.doi.org/10.1007/s00774-022-01347-1 Text en © The Japanese Society Bone and Mineral Research 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Fujita, Ryo Endo, Tsutomu Takahata, Masahiko Haraya, Kentaro Suzuki, Hisataka Oda, Itaru Kanayama, Masahiro Asano, Tsuyoshi Shigenobu, Keiichi Iwata, Akira Yamada, Katsuhisa Takeuchi, Hirohito Ohura, Hisanori Yoneoka, Daisuke Iwasaki, Norimasa Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
title | Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
title_full | Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
title_fullStr | Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
title_full_unstemmed | Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
title_short | Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
title_sort | real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244578/ https://www.ncbi.nlm.nih.gov/pubmed/35759143 http://dx.doi.org/10.1007/s00774-022-01347-1 |
work_keys_str_mv | AT fujitaryo realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT endotsutomu realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT takahatamasahiko realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT harayakentaro realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT suzukihisataka realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT odaitaru realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT kanayamamasahiro realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT asanotsuyoshi realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT shigenobukeiichi realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT iwataakira realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT yamadakatsuhisa realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT takeuchihirohito realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT ohurahisanori realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT yoneokadaisuke realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis AT iwasakinorimasa realworldpersistenceoftwiceweeklyteriparatideandfactorsassociatedwiththediscontinuationinpatientswithosteoporosis |